Targeted treatment of advanced and metastaticbreast cancer with lapatinib

References

• BaselgaJAverbuchSD2000ZD1839 (‘Iressa’) as an anticancer agentDrugs60Suppl 13340 discussion 41–211129170
   PubMed Web of Science ®Google Scholar
• BenceAKAndersonEBHalepotaMA2005Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjectsInvest New Drugs23394915528979
   PubMed Web of Science ®Google Scholar
• BendellJCDomchekSMBursteinHJ2003Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinomaCancer972972712784331
   PubMed Web of Science ®Google Scholar
• Beulz-RicheDRobertJRicheC2002Effects of paclitaxel, cyclophosphamide, ifosfamide, tamoxifen and cyclosporine on the metabolism of methoxymorpholinodoxorubicin in human liver microsomesCancer Chemother Pharmacol492748011914905
   PubMed Web of Science ®Google Scholar
• BudmanDRSoongRCalabroA2006Identification of potentially useful combinations of epidermal growth factor receptor tyrosine kinase antagonists with conventional cytotoxic agents using median effect analysisAnticancer Drugs17921816940802
   PubMed Web of Science ®Google Scholar
• BurrisHA3rdHurwitzHIDeesEC2005Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomasJ Clin Oncol2353051315955900
   PubMed Web of Science ®Google Scholar
• BursteinHJStornioloAMFrancoS2008A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancerAnn Oncol1910687418283035
   PubMed Web of Science ®Google Scholar
• CameronDCaseyMPressM2008A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analysesBreast Cancer Res Treat10.1007/s10549-007-9885-0
   Web of Science ®Google Scholar
• CersosimoRJ2006Gefitinib: an adverse effects profileExpert Opin Drug Saf54697916610973
   PubMed Web of Science ®Google Scholar
• ChangSParkerSLPhamT1998Inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program of the National Cancer Institute, 1975–1992Cancer822366729635529
   PubMed Web of Science ®Google Scholar
• ChowdhurySPickeringLMEllisPA2007Lapatinib: a novel dual tyrosine kinase inihibitorTarg Oncol210712
   Web of Science ®Google Scholar
• ChuIBlackwellKChenSSlingerlandJ2005The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancerCancer Res65182515665275
   PubMed Web of Science ®Google Scholar
• ChuQSSchwartzGde BonoJ2007Phase I and pharmacokinetic study of lapatinib in combination with capecitabine in patients with advanced solid malignanciesJ Clin Oncol253753817704424
   PubMed Web of Science ®Google Scholar
• ClarkKJKeithBRAlligoodK2002Pharmacokinetics and pharacodynamics of GW572016 following oral administration to female BT474-bearing CB-17 SCID miceAAPS PharmSci4W5286
   Google Scholar
• ClaytonAJDansonSJollyS2004Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancerBr J Cancer916394315266327
   PubMed Web of Science ®Google Scholar
• CooleySBurnsLJRepkaT1999Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neuExp Hematol2715334110517495
   PubMed Web of Science ®Google Scholar
• CrownJCameronDMartinAM2007Lapatinib (L) plus capecitabine (C) in HER2+ advanced breast cancer (ABC): report of updated efficacy and genearray dataEur J Cancer Suppl5212
   Web of Science ®Google Scholar
• CrownJPBurrisHA3rdBoyleF2008Pooled analysis of diarrhea events in patients with cancer treated with lapatinibBreast Cancer Res Treat10.1007/s10549-007-9860-9
   Web of Science ®Google Scholar
• Di LeoAGomezHAzizZ2007Lapatinib (L) with paclitaxel compared to paclitaxel as first-line treatment for patients with metastatic breast cancer: A phase III randomised, double-blind study of 580 patients [abstract]J Clin Oncol25S abstr 1011
   Google Scholar
• EmletDRBrownKAKocibanDL2007Response to trastuzumab, erlotinib, and bevacizumab, alone and in combination, is correlated with the level of human epidermal growth factor receptor-2 expression in human breast cancer cell linesMol Cancer Ther626647417938260
   PubMed Web of Science ®Google Scholar
• EngelRHKaklamaniVG2007HER2-positive breast cancer: current and future treatment strategiesDrugs6713294117547474
   PubMed Web of Science ®Google Scholar
• EwerMSVooletichMTDurandJB2005Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatmentJ Clin Oncol237820616258084
   PubMed Web of Science ®Google Scholar
• FinnRSGagnonRDi LeoA2008Lapatinib and paclitaxel in HER2-negative, extracellular domain (ECD) positive metastatic breast cancer (MBC) in a randomised phase III study [abstract]J Clin Oncol26Suppl abstr 1017
   Google Scholar
• ForceTKrauseDSVan EttenRA2007Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibitionNat Rev Cancer73324417457301
   PubMed Web of Science ®Google Scholar
• GaulMDGuoYAffleckK2003Discovery and biological evaluation of potent dual ErbB-2/EGFR tyrosine kinase inhibitors: 6-thiazolylquinazolinesBioorg Med Chem Lett136374012639547
   PubMed Web of Science ®Google Scholar
• GeyerCEForsterJLindquistD2006Lapatinib plus capecitabine for HER2-positive advanced breast cancerN Engl J Med35527334317192538
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline clinical trial register [online]Accessed May 27 2008 URL: http://ctr.gsk.co.uk/Summary/lapatinib/studylist.asp
   Google Scholar
• GoldsteinNIPrewettMZuklysK1995Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft modelClin Cancer Res1131189815926
   PubMed Web of Science ®Google Scholar
• GomezHLChavezMADovalDC2007Investigation of tumor biomarkers as response predictors in a monotherapy study with lapatinib (L) as a first line treatment in ErbB2 amplified women with breast cancer [abstract]J Clin Oncol2518S abstr 10562
   Google Scholar
• GomezHLDovalDCChavezMA2008Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancerJ Clin Oncol262940218458041
   PubMed Web of Science ®Google Scholar
• GordonANFinklerNEdwardsRP2005Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter studyInt J Gynecol Cancer157859216174225
   PubMed Web of Science ®Google Scholar
• GrazetteLPBoeckerWMatsuiT2004Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathyJ Am Coll Cardiol442231815582322
   PubMed Web of Science ®Google Scholar
• GuarneriVFrassoldatiACagossiK2008CHER LOB Trial: Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer – Safety report as per Independent Data Monitoring Committee (IDMC) and preliminary activity data [abstract]J Clin Oncol26Suppl abstr 580
   Google Scholar
• GuarneriVLenihanDJValeroV2006Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experienceJ Clin Oncol2441071516908934
   PubMed Web of Science ®Google Scholar
• HegdePSRusnakDBertiauxM2007Delineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profilesMol Cancer Ther616294017513611
   PubMed Web of Science ®Google Scholar
• HerendeenJMSmithDASteadA2004An open-label, fixed sequence, two period study to evaluate the potential induction of GW572016 metabolism by carbamazepine [abstract]J Clin Oncol2214S abstr 3081
   Google Scholar
• JohnstonSTrudeauMKaufmanB2008Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapyJ Clin Oncol2610667218212337
   PubMed Web of Science ®Google Scholar
• JonesSFHainsworthJDSpigelDR2004A phase I study of the dual kinase inhibitor GW572016 in combination with paclitaxel (EGF10009) [abstract]J Clin Oncol2214S abstr 2083
   Google Scholar
• KaufmanBTrudeauMEJohnstonS2008Clinical activity of lapatinib monotherapy in patients with HER2+ relapsed/refractory inflammatory breast cancer (IBC): Final results of the expanded HER2+ cohort in EGF103009 [abstract]J Clin Oncol26Suppl abstr 636
   Google Scholar
• KlijnJGBernsPMSchmitzPI1992The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patientsEndocr Rev133171313356
   PubMed Web of Science ®Google Scholar
• KonecnyGEPegramMDVenkatesanN2006Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cellsCancer Res661630916452222
   PubMed Web of Science ®Google Scholar
• KonishiJYamazakiKKinoshitaI2005Analysis of the response and toxicity to gefitinib of non-small cell lung cancerAnticancer Res254354115816608
   PubMed Web of Science ®Google Scholar
• KrolJLamECoombesC2007Critical role of FoxO3A transciption factor in response to therapy with EGFR inhibitors, gefitinib and lapatinib, in breast cancer [abstract]J Clin Oncol2518S abstr 21018
   Google Scholar
• LacoutureME2006Mechanisms of cutaneous toxicities to EGFR inhibitorsNat Rev Cancer68031216990857
   PubMed Web of Science ®Google Scholar
• LinNPaulDDierasV2007Lapatinib and capecitabine for the treatment of brain metastases in patients with HER2+ breast cancer – an updated analysis from EGF105084 [abstract]Breast Cancer Res Treat106S1 abstr 6076
   Google Scholar
• LinNUCareyLALiuMC2008aPhase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancerJ Clin Oncol261993918421051
   PubMed Web of Science ®Google Scholar
• LinNURochéHHDierasV2008bA physician-reported neurological signs and symptoms worksheet (NSS WS) in EGF105084: A phase II study of lapatinib (lap) for pts with recurrent brain metastases from HER2+ breast cancer (BC) [abstract]J Clin Oncol26Suppl abstr 1078
   Google Scholar
• LiptonACarneyWMartinA2007ASCO Breast Cancer Symposium 2007 Abstr 105
   Google Scholar
• LiuPCLiuXLiY2006Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cellsCancer Biol Ther56576416627989
   PubMed Web of Science ®Google Scholar
• MidgleyRSKerrDJFlahertyKT2007A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecanAnn Oncol182025917846021
   PubMed Web of Science ®Google Scholar
• MoyBGossPE2007Lapatinib-associated toxicity and practical management recommendationsOncologist127566517673607
   PubMed Web of Science ®Google Scholar
• NahtaREstevaFJ2007Trastuzumab: triumphs and tribulationsOncogene2636374317530017
   PubMed Web of Science ®Google Scholar
• NahtaRYuanLXDuY2007Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signalingMol Cancer Ther66677417308062
   PubMed Web of Science ®Google Scholar
• O’ConnorRClynesMDowlingP2007Drug resistance in cancer - searching for mechanisms, markers and therapeutic agentsExpert Opin Drug Metab Toxicol38051718028026
   PubMed Web of Science ®Google Scholar
• O’ShaughnessyJBlackwellKLBursteinH2008A randomised study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy [abstract]J Clin Oncol26Suppl abstr 1015
   Google Scholar
• PanditeLBurrisHAJonesS2004A safety, tolerability, and pharmacokinetic (PK) study of GW572016 in patients with solid tumours [abstract]J Clin Oncol2214SL abstr 3179
   Google Scholar
• PerezEAKoehlerMByrneJ2008Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trialsMayo Clin Proc836798618533085
   PubMed Web of Science ®Google Scholar
• Perez-SolerRSaltzL2005Cutaneous adverse effects with HER1/ EGFR-targeted agents: is there a silver lining?J Clin Oncol2352354616051966
   PubMed Web of Science ®Google Scholar
• PestalozziBCBrignoliS2000Trastuzumab in CSFJ Clin Oncol1823495110829059
   PubMed Web of Science ®Google Scholar
• PollackVASavageDMBakerDA1999Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic miceJ Pharmacol Exp Ther2917394810525095
   PubMed Web of Science ®Google Scholar
• PolliJWHumphreysJEHarmonKA2008The role of efflux and uptake transporters in N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactionsDrug Metab Dispos3669570118216274
   PubMed Web of Science ®Google Scholar
• PressMFFinnRSDi LeoA2008Correlation of HER2 gene amplification, HER2 and EGFR expression (protein and mRNA) with lapatinib efficacy in women with metastatic breast cancer [abstract]J Clin Oncol26Suppl abstr 1007
   Google Scholar
• RugoHSFrancoSMunsterP2008A phase II evaluation of lapatinib (L) and bevacizumab (B) in HER-2+ metastatic breast cancer (MBC) [abstract]J Clin Oncol26Suppl abstr 1042
   Google Scholar
• RusnakDWAlligoodKJMullinRJ2007Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell linesCell Prolif405809417635524
   PubMed Web of Science ®Google Scholar
• RusnakDWLackeyKAffleckK2001The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivoMol Cancer Ther1859412467226
   PubMed Web of Science ®Google Scholar
• SainsburyJRFarndonJRNeedhamGK1987Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancerLancet113984022884496
   PubMed Web of Science ®Google Scholar
• ScaltritiMRojoFOcanaA2007Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancerJ Natl Cancer Inst996283817440164
   PubMed Web of Science ®Google Scholar
• SeidmanAHudisCPierriMK2002Cardiac dysfunction in the trastuzumab clinical trials experienceJ Clin Oncol2012152111870163
   PubMed Web of Science ®Google Scholar
• Siegel-LakhaiWSBeijnenJHVervenneWL2007Phase I pharmacokinetic study of the safety and tolerability of lapatinib (GW572016) in combination with oxaliplatin/fluorouracil/leucovorin (FOLFOX4) in patients with solid tumorsClin Cancer Res13449550217671135
   PubMed Web of Science ®Google Scholar
• SlamonDGomezHLKabbinavarFF2008Randomised study of pazopanib + lapatinib vs. lapatinib alone in patients with HER2-positive advanced or metastatic breast cancer [abstract]J Clin Oncol26Suppl abstr 1016
   Google Scholar
• SlamonDJClarkGMWongSG1987Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogeneScience235177823798106
   PubMed Web of Science ®Google Scholar
• SlamonDJLeyland-JonesBShakS2001Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2N Engl J Med344117839211248153
   PubMed Web of Science ®Google Scholar
• SmithDABowenCHerendeenJM2004An open-label, randomized, two-way crossover study to evaluate the potential inhibition of GW572016 metabolism by ketoconazole [abstract]J Clin Oncol2214S abstr 3071
   Google Scholar
• SpectorNLXiaWBurrisH3rd2005Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignanciesJ Clin Oncol2325021215684311
   PubMed Web of Science ®Google Scholar
• SpectorNLYardenYSmithB2007Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cellsProc Natl Acad Sci U S A104106071217556544
   PubMed Web of Science ®Google Scholar
• StornioloAMPegramMDOvermoyerB2008Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancerJ Clin Oncol2633172318490651
   PubMed Web of Science ®Google Scholar
• SunagaNTomizawaYYanagitaniN2007Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapyLung Cancer56383917368623
   PubMed Web of Science ®Google Scholar
• SweetmanRLacoutureMEKoehlerM2007Skin events (SE) among 1,126 patients (Pts) treated with lapatinib (L), an oral dual Erb1/2 tyrosine kinase inhibitor (TKI) [abstract]J Clin Oncol2518S abstr 9102
   Google Scholar
• ToiMIwataHFujiwaraY2007Biomarker analyses in Japanese refractory advanced breast cancer patients treated with lapatinib monotherapy [abstract]San Antonio Breast Cancer Symposium abstr 5114
   Google Scholar
• ToiMTominagaTOsakiA1994Role of epidermal growth factor receptor expression in primary breast cancer: results of a biochemical study and an immunocytochemical studyBreast Cancer Res Treat295187912567
   PubMed Web of Science ®Google Scholar
• Vazquez-MartinAOliveras-FerrarosCColomerR2008Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb) in human breast carcinoma cellsAnn Oncol19109710918283037
   PubMed Web of Science ®Google Scholar
• VogelCLCobleighMATripathyD2002Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancerJ Clin Oncol207192611821453
   PubMed Web of Science ®Google Scholar
• von MinckwitzGJonatWFaschingP2005A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancerBreast Cancer Res Treat891657215692759
   PubMed Web of Science ®Google Scholar
• WoodERTruesdaleATMcDonaldOB2004A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cellsCancer Res646652915374980
   PubMed Web of Science ®Google Scholar
• XiaWBacusSHegdeP2006A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancerProc Natl Acad Sci U S A103779580016682622
   PubMed Web of Science ®Google Scholar
• XiaWGerardCMLiuL2005Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cellsOncogene2462132116091755
   PubMed Web of Science ®Google Scholar
• XiaWHusainILiuL2007Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancersCancer Res671170517283152
   PubMed Web of Science ®Google Scholar
• XiaWMullinRJKeithBR2002Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathwaysOncogene2162556312214266
   PubMed Web of Science ®Google Scholar
• YardenYSliwkowskiMX2001Untangling the ErbB signalling networkNat Rev Mol Cell Biol21273711252954
   PubMed Web of Science ®Google Scholar
• ZhouXSegretiACameronD2008Effect of lapatinib plus capecitabine (L+C) on quality of life (QOL) compared to capecitabine (C) alone ine ErbB+ metastatic breast cancer (MBC): an exploratoy analysis [abstract]J Clin Oncol26Suppl abstr 9532
   Google Scholar
• ZhouYLiSHuYP2006Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosisCancer Res664041116397255
   PubMed Web of Science ®Google Scholar